Black Diamond Therapeutics appoints Mark Velleca to Board of Directors

Black Diamond Therapeutics, Inc.

Appointed Mark Velleca, M.D., Ph.D. as Class I director effective August 9, 2021.
Determined independent under Nasdaq listing standards; not appointed to any committees initially.
Will receive standard non-employee director compensation, including initial equity award per company policy.
Velleca brings over 20 years biotech experience; previously CEO of G1 Therapeutics (led from Series A to FDA approval).
No transactions with company requiring disclosure; selected per Board recommendation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Velleca

Class I Director

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2021-08-09
Filed: August 10, 2021, 7:59 PM ET

appointed Mark Velleca, M.D., Ph.D. to serve on the Board as a Class I director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Velleca was appointed as Class I Director at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

appointed Mark Velleca, M.D., Ph.D. to serve on the Board as a Class I director

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-102855

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.